Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Randomized, Single Dose, Three-Arm, Parallel Open-Label Study to Characterize the Pharmacokinetics of 7.5 Mg Olanzapine Intranasal Spray and 7.5 Mg Olanzapine Intramuscular Injection After Administration to Healthy Male Adults Under Fasting Conditions

NCT06600477 is registered in ClinicalTrials.gov with Neurelis, Inc. as lead sponsor.

NCT NCT06600477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06600477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Randomized, Single Dose, Three-Arm, Parallel Open-Label Study to Characterize the Pharmacokinetics of 7.5 Mg Olanzapine Intranasal Spray and 7.5 Mg Olanzapine Intramuscular Injection After Administration to Healthy Male Adults Under Fasting Conditions
Lead sponsor
Neurelis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 16, 2023
Completion date
November 1, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy